Alto Neuroscience, Inc. (ANRO)
$
3.43
+0.02 (0.58%)
Key metrics
Financial statements
Free cash flow per share
-2.0913
Market cap
92.9 Million
Price to sales ratio
235.7023
Debt to equity
0.0341
Current ratio
18.4335
Income quality
0.8493
Average inventory
0
ROE
-0.4481
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company focused on drug development in psychiatry. The company reported selling, general, and administrative expenses of $21,614,000.00 indicating its operational overhead costs. With total costs and expenses amounting to $68,610,000.00 the company reflects its overall spending. The EBITDA ratio is 0.00 highlighting the company's operational efficiency in managing its expenses against earnings. As it narrows its market focus, the company achieved a revenue of $0.00 illustrating its aim to cater to specific therapeutic needs. Furthermore, the company reported an income before tax of -$61,431,000.00 showcasing its pre-tax profitability as it works on developing treatments such as ALTO-100 for major depressive disorder (MDD) and post-traumatic stress disorder, ALTO-300, a melatonergic agonist and serotonergic antagonist, and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for cognitive impairment related to schizophrenia. Additionally, its innovative pipeline includes the development of ALTO-203, a histamine H3 receptor inverse agonist, and ALTO-202, an investigational antagonist of the GluN2B subunit of the NMDA receptor for MDD, alongside a unique AI-enabled biomarker platform. In the market context, the stock is affordable at $2.68 making it suitable for budget-conscious investors. The stock maintains an average trading volume of 232,553.00 indicating moderate liquidity for potential investors. With a market capitalization of $92,866,725.00 the company is classified as a small-cap player, which distinguishes it within the broader financial landscape. As a key player in the Biotechnology industry, Alto Neuroscience contributes significantly to the overall market landscape, showcasing its dedication to mental health advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it seeks to address the complex challenges of psychiatric disorders through cutting-edge research and development.
Is Alto Neuroscience, Inc. (ANRO) a good investment?
Investing in Alto Neuroscience, Inc. (ANRO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Alto Neuroscience, Inc. (ANRO)'s stock forecast?
Analysts predict Alto Neuroscience, Inc. stock to fluctuate between $1.60 (low) and $15.04 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alto Neuroscience, Inc.'s market capitalization?
As of 2025-08-20, Alto Neuroscience, Inc.'s market cap is $92,866,725, based on 27,074,847 outstanding shares.
How does Alto Neuroscience, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alto Neuroscience, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alto Neuroscience, Inc. (ANRO) stock?
To buy Alto Neuroscience, Inc. (ANRO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANRO. Place an order (Market, Limit, etc.).
What is the best time to invest in Alto Neuroscience, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Alto Neuroscience, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.50 | Growth: 85.19%.
Where can I find Alto Neuroscience, Inc.'s investor relations reports?
Visit https://www.altoneuroscience.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alto Neuroscience, Inc.?
You can explore historical data from here
What is the all-time high and low for Alto Neuroscience, Inc. stock?
All-time high: $24 (2024-02-05) | All-time low: $1.60 (2025-04-04).
What are the key trends affecting Alto Neuroscience, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud.
globenewswire.com
Investors can contact the law firm at no cost to learn more about recovering their losses
prnewswire.com
SAN DIEGO , Aug. 18, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Alto Neuroscience, Inc. (NYSE: ANRO). Investors who purchased in excess of $100,000 in shares of Alto Neuroscience, Inc. (NYSE: ANRO) between February 2, 2024 and October 22, 2024, have certain options and there are short and strict deadlines running.
prnewswire.com
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
prnewswire.com
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on or about February 2, 2024 and/or between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), are encouraged to contact the firm before September 19, 2025.
globenewswire.com
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
globenewswire.com
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline.
prnewswire.com
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period").
globenewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
prnewswire.com
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud.
See all news
